cigna glp 1 2025 doubles down on GLP-1 support programs with 2 new launches Cigna dropping GLP-1 obesity drug
Description
10.1056/NEJMoa2301972
Expanding clinical evidence supporting cardiovascular benefits and weight-loss outcomes is driving strong demand worldwide
Structural MRI gives the most encouraging-looking number in the whole class, and it needs the most careful handling
Rotating injection sites and reviewing technique reduce risks
Even if your food choices haven't shifted dramatically, portion size alone reduces how much protein you consume each day
73 Currently, a Phase III trial (NCT04822181) investigating SEMAs effect on improving liver fibrosis is ongoing and is expected to conclude on April 25, 2029
